{"name":"Syndax Pharmaceuticals","slug":"syndax","ticker":"SNDX","exchange":"NASDAQ","domain":"syndax.com","description":"Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.","hq":"New York, NY","founded":0,"employees":"298","ceo":"Briggs Morrison","sector":"Hematology-Oncology Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":21.08,"stockChange":0.19,"stockChangePercent":0.91,"marketCap":"$1.9B","metrics":{"revenue":217174000,"revenueGrowth":223.6,"grossMargin":-23.2,"rdSpend":258784000,"netIncome":-285422000,"cash":361239008,"dividendYield":0,"peRatio":-92.6,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2024-01-01","label":"Revuforj first approved","drug":"Revuforj","drugSlug":"revumenib","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-12-15","label":"Revuforj PHASE1,PHASE2 readout","drug":"Revuforj","drugSlug":"revumenib","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-06-01","label":"entinostat patent cliff ($0.0B at risk)","drug":"entinostat","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Revuforj","genericName":"REVUMENIB","slug":"revumenib","indication":"relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation","status":"marketed"}]}],"pipeline":[{"name":"Revuforj","genericName":"REVUMENIB","slug":"revumenib","phase":"marketed","mechanism":"Revuforj works by inhibiting an enzyme that is involved in the growth and survival of cancer cells.","indications":["relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation","relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Syndax Pharmaceuticals reported its fourth quarter and full year 2023 financial results, highlighting revenue growth and a strong pipeline.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Syndax Pharmaceuticals Announces Collaboration with Pfizer to Develop Entinostat in Combination with Pfizer's Aromatase Inhibitors","summary":"Syndax Pharmaceuticals entered into a collaboration with Pfizer to develop entinostat in combination with Pfizer's aromatase inhibitors for the treatment of hormone receptor-positive breast cancer.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"trial","headline":"Syndax Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial of Entinostat in Combination with Pembrolizumab in Patients with Advanced or Metastatic Melanoma","summary":"Syndax Pharmaceuticals announced positive topline results from a Phase 2 trial of entinostat in combination with pembrolizumab in patients with advanced or metastatic melanoma.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNckJhQ3oxRUo2T05ycTF2cGoxM2ZOcy0tRTJIVU9jNTlxSU94Y1l2ODlTVVNYYWJBWEVxQ1lWa3ZCNG1NRVZwQ3V0U3pTbHcwNlNYQnhhV1RjNk41UHdEWU9zN1FjSUFKY080S0J4bVIwUlU1cV85UVVGNkJqVkZWVXNaU0xReC00bnFrdElwNTNQREM5ZkRzSlZiQVFPenphbHpz?oc=5","date":"2026-03-18","type":"pipeline","source":"Seeking Alpha","summary":"Syndax Pharma: Two Drug Launches Fuel Transformational Growth (NASDAQ:SNDX) - Seeking Alpha","headline":"Syndax Pharma: Two Drug Launches Fuel Transformational Growth (NASDAQ:SNDX)","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQZVBXSjZ2Tzc1NEhHSDF0RFBQaVE0M3ZHeGV1a09MdnFES0NMTjBEdm1GVkRQMjQ3aXRYNW1SVnhaRVhnY01WYTcwSk9GTmxmR3psMHNUVTBTWVBmcC0tcG9yakl2RjRrbDdtS0pibU14U0JQY0hGSnpyWUtjSXhHdS05UVZsd2hfVlk1cDUtWHVweFoyVUZZN3h6R1V1c2U5VWRFalJQc25kNG01eGc?oc=5","date":"2026-02-10","type":"pipeline","source":"Investing.com","summary":"Syndax Pharma CFO Goldan sells $71k in shares - Investing.com","headline":"Syndax Pharma CFO Goldan sells $71k in shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOQXhmMmlXZVpnaXhuUno2ZWpTMVVVU2JnSS1YeGNqTnktN1RMM0JoVmNDTDJ4U0djcmlrOUhlQzI5dkJOTWFLMkRRSUExc1c3dkJJY3RkaTY0Tm0xU2J3ekh3XzFBMmRUWHl6UHM5bWFPZmJkNS1xbXFrZkxEZUU4V3l0Ylo1cUc4dHJhdVYwbFVLZw?oc=5","date":"2025-12-17","type":"pipeline","source":"Seeking Alpha","summary":"Syndax Pharma: Continuing Execution In AML (NASDAQ:SNDX) - Seeking Alpha","headline":"Syndax Pharma: Continuing Execution In AML (NASDAQ:SNDX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNaU03QXJDQUt6LVB0azN2aUNiazZ4TGh2RlMwX0k1QzJ4ZHNMamQxMlBnSzFPeGl6ZXd4UmVKQTlxTVd2cFljZTl0R0RUWFlkd0ZHZzVraTRVTTVJRnp1UTZvakpQMW1XVFZvbnBJbXBZMTYtM0xlVEdELU9NZ1BPNlJjUDlLTkEyTkliQVJoRnFOZFUxdG9uYjA5NTRoZGFtSWo5eWhFNXpBUQ?oc=5","date":"2025-11-15","type":"deal","source":"Insider Monkey","summary":"10 Best Small-Cap Biotech Stocks to Buy According to Analysts - Insider Monkey","headline":"10 Best Small-Cap Biotech Stocks to Buy According to Analysts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNSkdyWW1DZjJkU1NaNkVyNjVfQmZOWHVwUmJsYWpvY1lGY25tNkZ3YzFWc09oYUMxYWNHSDl2eTRkZHpJNGdEWGdsc0FBNThGdlphc2Y5SE9xaGNMN2lQLUlNRHFKSTBhLU1UamNFaWVjeFVOSGxkX2pSb0I5X3BaX3NBQzdYdmVrRmdSck5uWFB6ekNWRnlfRW44bnFvbVJhZDhVcGJrUkZHeDBNZmJNSFkzRTFjUmR2WnFBZjNn?oc=5","date":"2025-11-05","type":"pipeline","source":"Seeking Alpha","summary":"Syndax Pharmaceuticals: Thesis Firing On All Cylinders, Sales Acceleration In 2026 (SNDX) - Seeking Alpha","headline":"Syndax Pharmaceuticals: Thesis Firing On All Cylinders, Sales Acceleration In 2026 (SNDX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNUkhKOFZwYmZMTnl5UUZuSy12VnJuZlBZMVRMTUZSSDd6S0lkckVVUWxxZ0pMREVtUGRyOEllZHFIN1A5bUVPdlF6X1I3dHR5Y3B1bHpPUC1xT0gtM3FuLVdWSTVrRkxvZDFvLWpYeDZtWnZ0SklZYkhCSGJJRzEzLXZDU2JMeTlXV2JLSWR5WVg?oc=5","date":"2025-11-04","type":"pipeline","source":"Yahoo Finance","summary":"Syndax Pharmaceuticals (SNDX): Losses Worsen, Growth Forecasts Test Bullish Market Narratives - Yahoo Finance","headline":"Syndax Pharmaceuticals (SNDX): Losses Worsen, Growth Forecasts Test Bullish Market Narratives","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQYXFKSlhvNzdfRUZRdW5pMGFaYVVGU281eHRiY29NRmJNRS1seTNKZ3I5dWQ0NElkdHdMQzlwdzBUUVdKY1ZkNFpmNVlyLUtuLW9hR0RIQ2JrcXpIamRneEFDRDlYcTFRd1A0cWN2X2dvSmFlNEg5aXVDcE5iWTZIcFhxRGhIbUU0UndR?oc=5","date":"2025-10-27","type":"regulatory","source":"The Pharma Letter","summary":"New FDA green light for Syndax’ Revuforj - The Pharma Letter","headline":"New FDA green light for Syndax’ Revuforj","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxORGk2LTI1VGZ6MmFPWGVRUVIzZHkxYTRsbW5BNzlSNEZZQml6Wl95bjhZN3BHMDdFZnlDM0o4c1J4MlFFUnZqY2hwWi1IVmtIRE5FQ1JmSUcybzBTd0RlYVVNaUhDbnF3XzY3MHhzM3VRZ2k1MlZPc0Rlc1JmaGl3R3d2dWJ4a3JQQTZOc2hGNzktd0k3ekZwTEtLY3pNZnlHRmVKUzc3TnRhTHg0ZUZodEs5MGJLeEFnUmJJ?oc=5","date":"2025-10-24","type":"regulatory","source":"Stock Titan","summary":"Syndax (NASDAQ: SNDX) wins FDA approval as Revuforj first for R/R NPM1 AML, KMT2A leukemia - Stock Titan","headline":"Syndax (NASDAQ: SNDX) wins FDA approval as Revuforj first for R/R NPM1 AML, KMT2A leukemia","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQQW9vUEFXMEJxRlhPV1FiN0xkMEJTVnBhNUpqY0ZmTmNHNEhMV29NcTNtaVU2RW45blpadnR3b21BZTZvZkl1aC1sLXoyaFJYU3hQc2dFZVZ4UHpPNEpHaHdpa3pCQy1hVUZDOElKM2U4NnlvMlpVbTR1T1hMOTdZalJIc3FKM3pfdlRIYWRCcGJENzd4emc?oc=5","date":"2025-10-24","type":"pipeline","source":"Benzinga","summary":"Why Is Syndax Stock Down Today? - Syndax Pharmaceuticals (NASDAQ:SNDX) - Benzinga","headline":"Why Is Syndax Stock Down Today? - Syndax Pharmaceuticals (NASDAQ:SNDX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQUEVtcndYVF9HTlRTaUtkQU5TNHkyTmFhMy15aTR0VkxTd1lnaUNOSG91WkpLYWozQVRNYXkwZGlSaDdVcDYxVmROcVVVeFYweTNOengzSnJFNV94cHUtdkJXc0FoUGRvMW02UWlVc2cwWUVVbkt6NmZVS2hNOXlGYUNNVE5DcFM1TGlWag?oc=5","date":"2025-09-25","type":"earnings","source":"Yahoo Finance","summary":"When Will Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Turn A Profit? - Yahoo Finance","headline":"When Will Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Turn A Profit?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQTy1MdGVLU001NnlfdlRibjYwY3g2MWZJeWsySU1NQnlrcXd2WHQ2YWRnT25YZGxKVVF6UDhkaXVId3JfNzRwc0MtSmY3eVJIb1E1QVZmNXFZOVRYSG5zNGt0MnlhWDUxNlkwdkh0V085ZTVXS3l4UVRuUnZuZnhHcXJ6RHBXd045ZmZwNTROZnk3ekRVaHZuQy1MNXZDLVNHR201X3hVUnlHYnZBNHduNzlSd0djdnot?oc=5","date":"2025-07-08","type":"regulatory","source":"Seeking Alpha","summary":"Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals - Seeking Alpha","headline":"Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQdlg2Mk9EdWdXc0dWekdqTWpNbkU4MXNJUGEwNXV2TkQ4V0w4ZkxEcXBsZS1kYWxFVVlvQjBzcFNqejUydHdrYXNNcTdoRjFhRWE5WlNKMElSOW9XSkpJN2RDbG1rekxQVFpfWmtmWU5fcnhfUnQxbDAyTm9KcWJSMDZ4aFZZX0U0bXhZWUtHSnVfN0JUWWV1MUJFcVgwNE5DLUV2UVV3NHB0bUE?oc=5","date":"2024-11-18","type":"regulatory","source":"MedCity News","summary":"Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval - MedCity News","headline":"Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval","sentiment":"positive"}],"patents":[{"drugName":"entinostat","drugSlug":"entinostat","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":7,"keyCompetitors":["Clovis Oncology","Array BioPharma","Pfizer"],"therapeuticFocus":["Hematology-Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":172352000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":172352000,"period":"2025-12-31"},{"value":23680000,"period":"2024-12-31"},{"value":23680000,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"},{"value":0,"period":"2023-12-31"}],"grossProfit":165382000,"grossProfitHistory":[{"period":"2025-12-31","value":165382000},{"period":"2024-12-31","value":22854000},{"period":"2023-12-31","value":0},{"period":"2022-12-31","value":0}],"rdSpend":258784000,"rdSpendHistory":[{"period":"2025-12-31","value":258784000},{"period":"2024-12-31","value":241647000},{"period":"2023-12-31","value":163032000},{"period":"2022-12-31","value":118499000}],"sgaSpend":179682000,"operatingIncome":-273084000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-273084000},{"period":"2024-12-31","value":-339672000},{"period":"2023-12-31","value":-229954000},{"period":"2022-12-31","value":-151757000}],"netIncome":-285422000,"netIncomeHistory":[{"period":"2025-12-31","value":-285422000},{"period":"2024-12-31","value":-318758000},{"period":"2023-12-31","value":-209360000},{"period":"2022-12-31","value":-149338000}],"eps":-3.29,"epsHistory":[{"period":"2025-12-31","value":-3.29},{"period":"2024-12-31","value":-3.72},{"period":"2023-12-31","value":-2.98},{"period":"2022-12-31","value":-2.46}],"cash":134930000,"cashHistory":[{"period":"2025-12-31","value":134930000},{"period":"2024-12-31","value":154083000},{"period":"2023-12-31","value":295394000},{"period":"2022-12-31","value":74356000}],"totalAssets":529706000,"totalLiabilities":465076000,"totalDebt":345432000,"equity":64630000,"operatingCashflow":-322980000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-322980000},{"period":"2024-12-31","value":-274903000},{"period":"2023-12-31","value":-160601000},{"period":"2022-12-31","value":-133675000}],"capex":-187000,"capexHistory":[{"period":"2025-12-31","value":-187000},{"period":"2021-12-31","value":-129000}],"freeCashflow":-323167000,"dividendsPaid":null,"buybacks":null,"employees":298,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":37588000,"ebit":-30827000,"ebitda":-30823000,"period":"2026-03-31","revenue":64864000,"epsBasic":-0.48,"netIncome":-42673000,"rdExpense":58845000,"epsDiluted":-0.48,"grossProfit":62231000,"operatingIncome":-34202000},{"sga":49929000,"ebit":-58421000,"ebitda":-58418000,"period":"2025-12-31","revenue":68728000,"epsBasic":-0.78,"netIncome":-68014000,"rdExpense":78641000,"epsDiluted":-0.78,"grossProfit":66022000,"operatingIncome":-62548000},{"sga":44917000,"ebit":-52432000,"ebitda":-52429000,"period":"2025-09-30","revenue":45871000,"epsBasic":-0.7,"netIncome":-60715000,"rdExpense":56280000,"epsDiluted":-0.7,"grossProfit":43771000,"operatingIncome":-57426000},{"sga":43805000,"ebit":-63989000,"ebitda":-63989000,"period":"2025-06-30","revenue":37958000,"epsBasic":-0.83,"netIncome":-71847000,"rdExpense":62227000,"epsDiluted":-0.83,"grossProfit":36679000,"operatingIncome":-69353000},{"sga":41031000,"ebit":-76795000,"ebitda":-76795000,"period":"2025-03-31","revenue":20042000,"epsBasic":-0.98,"netIncome":-84846000,"rdExpense":61636000,"epsDiluted":-0.98,"grossProfit":19157000,"operatingIncome":-83757000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":21.08,"previousClose":20.89,"fiftyTwoWeekHigh":25.59,"fiftyTwoWeekLow":8.58,"fiftyTwoWeekRange":"8.58 - 25.59","fiftyDayAverage":22.89,"twoHundredDayAverage":18.86,"beta":0.41,"enterpriseValue":1835184512,"forwardPE":-92.6,"priceToBook":28.53,"priceToSales":8.6,"enterpriseToRevenue":8.45,"enterpriseToEbitda":-8.19,"pegRatio":0,"ebitda":-224168000,"ebitdaMargin":-103.2,"freeCashflow":-186258496,"operatingCashflow":-278163008,"totalDebt":345360000,"debtToEquity":829.8,"currentRatio":5.47,"returnOnAssets":-25.2,"returnOnEquity":-189.5,"analystRating":"1.2 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":12,"targetMeanPrice":39.25,"targetHighPrice":57,"targetLowPrice":29,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.7,"institutionHeldPercent":115.7,"sharesOutstanding":88610027,"floatShares":75100542,"sharesShort":19911327,"shortRatio":12.85,"shortPercentOfFloat":22.5,"epsTrailing":-2.79,"epsForward":-0.23,"revenuePerShare":2.49,"bookValue":0.74,"officers":[{"age":54,"name":"Mr. Michael A. Metzger M.B.A.","title":"CEO & Director"},{"age":54,"name":"Mr. Keith Alan Goldan CPA","title":"CFO, Treasurer & Principal Accounting Officer"},{"age":46,"name":"Mr. Luke J. Albrecht J.D.","title":"Senior VP, General Counsel & Secretary"},{"age":56,"name":"Mr. Steven  Closter","title":"Chief Commercial Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://syndax.com","phone":"781 419 1400"}}